

### REMARKS

Claims 1-8, and 17-18) are pending in this application. Claims 9-16 are cancelled without prejudice.

The Examiner required restriction to one of the following groups:

**Group I** (claims 1-8, 17-18), drawn to intravenous nanoparticles; and

**Group II** (claims 9-16), drawn to a method for producing intravenous nanoparticles.

Applicants hereby elect to prosecute the claims of Group I (claims 1-8, and 17-18). Claims 9-16 are cancelled without prejudice to re-filing the non-elected claims in a divisional application.

The examiner further stated three election requirements.

#### **First Election**

Applicants were required to elect whether or not the low-molecular weight, water-soluble and non-peptide drug has a phosphate group -- see pages 3-4 of the enclosed Office Action. Applicants elect that the low-molecular weight, water-soluble and non-peptide drug has a phosphate group, as specifically claimed in claim 5.

#### **Second Election**

Applicants were required to elect whether or not the low-molecular weight, water-soluble and non-peptide drug has a carboxyl group -- see page 4 of the enclosed Office Action. Applicants elect that the low-molecular weight, water-soluble and non-peptide drug has a carboxyl group, as specifically claimed in claim 6.

### **Third Election**

Finally, applicants were further required to elect a class of drug from the list in Claims 7 and 15 -- see page 4-5 of the enclosed Office Action. Applicants elect a prostanoid.

If the Examiner has any questions, he is respectfully requested to contact the undersigned. The Commissioner is hereby authorized to charge any additional fees, or to credit any overpayment, to Deposit Account No. 50-3195.

Respectfully submitted,

Date: November 12, 2007

/Manette Dennis/  
Manette Dennis (Reg. No. 30,623)  
Ostrager Chong Flaherty & Broitman, PC  
570 Lexington Avenue, Floor 17  
New York, NY 10022-6894  
Tel.: 212 681-0600  
Fax: 212 681-0300  
[mdennis@ocfblaw.com](mailto:mdennis@ocfblaw.com)